摘要
目的采用代谢组学技术,筛选可以用于预测曲妥珠单抗辅助治疗人类表皮生长因子受体-2(HER-2)阳性乳腺癌疗效的生物标志物。方法收集2017年1月至2019年12月金华市人民医院治疗的乳腺癌患者60例的血清样本,分为化疗组(30例)和化疗+曲妥珠单抗治疗组(30例),分别采用超高效液相色谱-四级杆/静电场轨道阱高分辨质谱(UHPLC-Q-Orbitrap HRMS)技术和SIMCA 14.1软件中的多元变量模式对样本及数据进行检测和分析。结果两组代谢物构建的正交偏最小二乘判别分析(OPLS-DA)模型稳健性良好,以P<0.05且VIP>1.0为筛选条件,筛选并鉴定出8个差异代谢物,可用于预测曲妥珠单抗辅助治疗HER-2阳性乳腺癌的疗效。结论代谢组学技术可揭示化疗+曲妥珠单抗组治疗HER-2阳性乳腺癌血清中内源性代谢物的变化特点,筛选出的生物标志物可用于疗效预测,同时为研究曲妥珠单抗的疗效评价提供新思路。
Objective To screen the biomarkers that can be used to predict the efficacy of trastuzumab in adjuvant treatment of human epidermal growth factor receptor-2-positive breast cancer by metabonomics.Methods Serum samples of 60 patients with human epidermal growth factor receptor-2-positive breast cancer who received treatment in Jinhua People's Hospital from January 2017 to December 2019 were retrospectively analyzed.These serum samples were divided into a chemotherapy group(n=30)and a chemotherapy+trastuzumab group(n=30).Two groups of samples were analyzed using the ultra-high performance liquid chromatography coupled to quadrupole high-resolution orbital ion trap mass spectrometry(UHPLC-Q-Orbitrap-HRMS)technique and the SIMCA 14.1 software.Results The multivariate orthogonal partial least squares-discrimination analysis(OPLS-DA)models constructed to verify differences in metabolites between the two groups had good reliability.Taking P<0.05 and VIP>1.0 as the screening conditions,eight different metabolites were screened and identified.Therefore,the constructed OPLS-DA models could be used to predict the efficacy of trastuzumab in the adjuvant treatment of human epidermal growth factor receptor-2-positive breast cancer.Conclusion Metabonomics technology can reveal the changes in serum endogenous metabolites in patients with human epidermal growth factor receptor-2-positive breast cancer who receive chemotherapy combined with trastuzumab.The selected biomarkers can be used to predict the curative effect and provide a new idea for evaluating the efficacy of trastuzumab.
作者
许维东
姚慧韬
张新平
牛艳昕
罗信国
施金俏
Xu Weidong;Yao Huitao;Zhang Xinping;Niu Yanxin;Luo Xinguo;Shi Jinqiao(Department of Laboratory Medicine,Jinhua People's Hospital,Jinhua 321000,Zhejiang Province,China;Department of Thoracic Surgery,Jinhua People's Hospital,Jinhua 321000,Zhejiang Province,China;Department of Obstetrics and Gynecology,Jinhua People's Hospital,Jinhua 321000,Zhejiang Province,China;Department of Hematology,Jinhua People's Hospital,Jinhua 321000,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2021年第2期184-189,共6页
Chinese Journal of Primary Medicine and Pharmacy
关键词
人类表皮生长因子受体-2阳性乳腺癌
代谢组学
曲妥珠单抗
超高效液相色谱-四级杆/静电场轨道阱高分辨质谱
生物标志物
差异代谢物
氨基酸
统计分析
Human epidermal growth factor receptor-2 positive breast cancer
Metabolomics
Trastuzumab
Ultra-high performance liquid chromatography-quadrupole/orbitrap high resolution mass spectrometry
Biomarker
Differential metabolites
Amino acid
Statistical analysis